Research Papers:

MicroRNA-372 inhibits endometrial carcinoma development by targeting the expression of the Ras homolog gene family member C (RhoC)

Bo-Liang Liu _, Kai-Xuan Sun, Zhi-Hong Zong, Shuo Chen and Yang Zhao

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:6649-6664. https://doi.org/10.18632/oncotarget.6544

Metrics: PDF 1591 views  |   HTML 2535 views  |   ?  


Bo-Liang Liu1, Kai-Xuan Sun1, Zhi-Hong Zong2, Shuo Chen1, Yang Zhao1

1Department of Gynecology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China

2Department of Biochemistry and Molecular Biology, College of Basic Medicine, China Medical University, Shenyang 100013, China

Correspondence to:

Yang Zhao, e-mail: [email protected]

Keywords: endometrial carcinoma, microRNA-372, RhoC, tumorigenesis, progression

Received: July 23, 2015     Accepted: November 16, 2015     Published: December 09, 2015


Here we explore the role of microRNA-372 (miR-372) in tumorigenesis and development of endometrial adenocarcinoma (EC) and analyze the underlying mechanism. We found that miR-372 expression is much lower in EC than normal endometrial specimens. Cell function experiments demonstrated that miR-372 overexpression suppressed cell proliferation, migration, and invasion, and led to a G1 phase arrest and promoted the apoptosis of endometrial carcinoma cells in vitro. The nude mouse xenograft assay demonstrated that miR-372 overexpression suppressed tumor growth. RT-PCR and Western blot assays detected the expression of known targets of miR-372 in other malignant tumors and found Cyclin A1 and Cyclin-dependent Kinase 2 (CDK2) was downregulated by miR-372. Bioinformatic predictions and dual-luciferase reporter assays found that RhoC was a possible target of miR-372. RT-PCR and Western blot assays demonstrated that miR-372 transfection reduced the expression of RhoC, matrix metalloproteinase 2 (MMP2) and MMP9, while it increased the expression of cleaved poly (ADP ribose) polymerase (PARP) and bcl-2-associated X protein (Bax). The cell function experiments that transfected siRNA with RhoC showed the same trend as those which were transfected with miR-372. Taken together, our results demonstrated for the first time that miR-372 suppresses tumorigenesis and the development of EC; RhoC is a new and potentially important therapeutic target.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6544